ProtoKinetix Inc (PKTX)

[Past and present]

***PKTX.. This was from the Protokinetix's Investors Meeting..Feb. 11th, 2022

...ProtoKinetix has patent coverage for the composition of matter for the family of AAGP compounds including PKX-001 in US, Europe & Canada, Internationally, along with processing IP shared with AmbioPharm Inc. to secure supply and meet distribution needs globally.

...Composition of Matter and Method of use patent families (P2594; P2628; P3601; P5136; P5168; P5386 on File at Benoit-Cote LLP) for PKX-001 have been secured inan ocular setting out to year 2041.

...Specifically, for enhancing neurosensory precursor cells (NPC; e.g. photoreceptor
precursor cells), and for the treatment of dry eye disease; including hypo-immune efficacy.

***Additional for transplantation/cryopreservation extend to year 2042+